270 related articles for article (PubMed ID: 23760676)
21. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
22. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
[TBL] [Abstract][Full Text] [Related]
23. [Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
Huang YH; He XH; Qin Y; Yang S; Lü Z; Dong M; Zhou SY; Liu P; Zhang CG; Yang JL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):385-9. PubMed ID: 22883463
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
25. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
Tomita N; Takasaki H; Miyashita K; Fujisawa S; Ogusa E; Matsuura S; Kishimoto K; Numata A; Fujita A; Ohshima R; Kuwabara H; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Fujimaki K; Taguchi J; Sakai R; Ishigatsubo Y
Br J Haematol; 2013 May; 161(3):383-8. PubMed ID: 23432318
[TBL] [Abstract][Full Text] [Related]
26. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
Ok CY; Li L; Xu-Monette ZY; Visco C; Tzankov A; Manyam GC; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Chen J; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ai W; Ponzoni M; Ferreri AJ; Farnen JP; Møller MB; Bueso-Ramos CE; Miranda RN; Winter JN; Piris MA; Medeiros LJ; Young KH
Clin Cancer Res; 2014 May; 20(9):2338-49. PubMed ID: 24583797
[TBL] [Abstract][Full Text] [Related]
28. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.
Song CG; Huang JJ; Li YJ; Xia Y; Wang Y; Bi XW; Jiang WQ; Huang HQ; Lin TY; Li ZM
PLoS One; 2015; 10(7):e0133973. PubMed ID: 26222726
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
31. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
32. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
33. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
[TBL] [Abstract][Full Text] [Related]
34. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.
Tisi MC; Cupelli E; Santangelo R; Maiolo E; Alma E; Giachelia M; Martini M; Bellesi S; D'Alò F; Voso MT; Pompili M; Leone G; Larocca LM; Hohaus S
Leuk Lymphoma; 2016; 57(3):628-34. PubMed ID: 26458141
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
[TBL] [Abstract][Full Text] [Related]
36. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
Sato A; Nakamura N; Kojima M; Ohmachi K; Carreras J; Kikuti YY; Numata H; Ohgiya D; Tazume K; Amaki J; Moriuchi M; Miyamoto M; Aoyama Y; Kawai H; Ichiki A; Hara R; Kawada H; Ogawa Y; Ando K
Cancer Sci; 2014 Sep; 105(9):1170-5. PubMed ID: 24974976
[TBL] [Abstract][Full Text] [Related]
38. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis.
Diem S; Ess S; Cerny T; Früh M; Hitz F
Eur J Intern Med; 2014 Jul; 25(6):577-82. PubMed ID: 24881010
[TBL] [Abstract][Full Text] [Related]
39. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
[TBL] [Abstract][Full Text] [Related]
40. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
